Order of Cabazitaxel and Abiraterone Does Not Affect Survival in mCRPC Treated Previously With Docetaxel
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
CAST: A Retrospective Analysis of Cabazitaxel and Abiraterone Acetate Sequential Treatment in Patients With Metastatic Castrate-Resistant Prostate Cancer Previously Treated With Docetaxel
Int. J. Cancer 2015 Mar 15;136(6)E760-E772, MD Wissing, JL Coenen, P van den Berg, HM Westgeest, AJ van den Eertwegh, IM van Oort, MM Bos, AM Bergman, P Hamberg, AJ Ten Tije, M Los, MP Lolkema, R de Wit, H GelderblomFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.